-
Related books
Davis's Drug Guide for Nurses, with Resource Kit CD-ROM
by Judith Hopfer Deglin and April Hazard Vallerand (Paperback - Jun 12, 2008)
Excerpt:
... "839 miscellaneous amoxapine 1270 bupropion 241 nefazodone 869 selegiline transderma11099 trazodone 1200 venlafaxine 1222, 1325" ...
More about this bookThe Nursing Mother's Companion: Revised Edition
by Kathleen Huggins (Paperback - Mar 1, 2005) - Deluxe Edition
Excerpt:
... "Limited data indicate that trazodone is also probably safe during nursing, but watch for excessive" ...
More about this bookTrazodone: An entry from Thomson Gale's <i>Gale Encyclopedia of Mental Disorders</i>
by Jack, Pharm.D. Raber (Digital - 2003) - HTML
More about this bookSymposium on Trazodone (Neuropsychobiology,)
by C. L. Cazzullo, K. Heinrich, and R. Ropert (Paperback - Jun 1986)
More about this bookTrazodone 1973: Symposium Proceedings (Modern problems of pharmacopsychiatry)
by Thomas A. Ban and B. Silvestrini (Hardcover - Jan 1, 1974)
More about this bookThe investigation of electrospun polymer nanofibers as a solid-phase extraction sorbent for the determination of trazodone in human plasma [An article from: Analytica Chimica Acta]
![The investigation of electrospun polymer nanofibers as a solid-phase extraction sorbent for the determination of trazodone in human plasma [An article from: Analytica Chimica Acta]](http://ecx.images-amazon.com/images/I/415FBN4EPVL._SL160_AA115_.jpg)
by X. Kang, C. Pan, Q. Xu, and Y. Yao (Digital - Mar 21, 2007) - HTML
More about this bookTrazodone - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References
by ICON Health Publications (Paperback - Jan 28, 2004)
More about this bookTrazodone. Modern Problems of Pharmacopsychiatry Volume 9
by Th[omas] A[rthur] (born 1929) &amp; Silvestrini, B., eds Ban (Hardcover - 1974)
More about this bookTrazodone: A Summary of UK Studies - Workshop Proceedings
(Paperback - Sep 1982) - Import
More about this bookTrazodone Second Clinical Workshop: A summary of UK studies, July 1983
(Paperback - 1983)
More about this bookThe effect of mianserin add-on, on the intensity of opioid withdrawal symptoms during detoxification program-a randomized, double blind, placebo controlled, ... study [An article from: Addictive Behaviors]
![The effect of mianserin add-on, on the intensity of opioid withdrawal symptoms during detoxification program-a randomized, double blind, placebo controlled, ... study [An article from: Addictive Behaviors]](http://ecx.images-amazon.com/images/I/41J08AVSFVL._SL160_AA115_.jpg)
by I. Herman, D. Shamir, R. Bar-Hamburger, and C.G. Pick (Digital - Jul 1, 2005) - HTML
More about this bookThe Anxiety & Phobia Workbook, Fourth Edition
by Edmund J. Bourne (Paperback - May 2005)
More about this book
medicine: trazodone
trazodone description
Go to trade names and prices
Trazodone (Desyrel, Beneficat, Deprax, Desirel, Molipaxin, Thombran, Trazorel, Trialodine, Trittico) is a psychoactive drug of the piperazine and triazolopyridine chemical classes that has antidepressant, anxiolytic, and hypnotic properties. It has been advertised that its therapeutic benefits become noticeable within the first week of administration. Trazodone has considerably less prominent anticholinergic (dry mouth, constipation, tachycardia) and sympatholytic (hypotension, sexual dysfunction consisting of erectile dysfunction and anorgasmia) side effects in comparison to most of the tricyclic antidepressants (TCAs) and tetracyclic antidepressants (TeCAs).
History
Trazodone was originally discovered and developed in Italy in the 1960s by Angelini research laboratories as a second-generation antidepressant. It was developed according to the mental pain hypothesis, which was postulated from studying patients and which proposes that major depression is associated with a decreased pain threshold. Trazodone was patented and marketed in many countries all over the world. It was approved by the Food and Drug Administration (FDA) at the end of 1981. It is closely related to nefazodone (Serzone).
Indications
Clinical depression with or without anxiety.Insomnia. (in some countries, this is an off-label use)
Fibromyalgia, to aid in sleeping.
Control of nightmares or other sleep disturbances.
Off-label and investigational uses
Panic disorder.Diabetic neuropathy.
Bulimia nervosa.
Obsessive-compulsive disorder (OCD).
Alcohol withdrawal.
Schizophrenia and other psychoses.
Antidepressant augmentation
Trazodone is often used in conjunction with selective serotonin reuptake inhibitors (SSRIs), like fluoxetine (Prozac) and has been noted to help with the anxiety that can result from beginning treatment with such antidepressants. Trazodone has been prescribed to children as an aid to other antidepressants as well.
Pharmacology
Trazodone inhibits the reuptake of serotonin, but possesses a far lower affinity for the serotonin transporter (SERT) than drugs in the selective serotonin reuptake inhibitor (SSRI) class, such as fluoxetine (Prozac) and citalopram (Celexa). Trazodone's anxiolytic and antidepressant effects may be due to its antagonistic effects at the 5-HT2A and 5-HT2C receptors. Its sedative-hypnotic effects may stem from its strong antagonistic activity at the 5-HT2A and alpha-1 adrenergic receptor in addition to its moderate antagonistic activity at the H1 receptor.
Pharmacokinetics
Trazodone is well absorbed after oral administration with mean peak blood levels obtained at approximately 1 hour after ingestion. Absorption is somewhat delayed and enhanced by food. The mean blood elimination half-life is biphasic: the first phase's half-life is 3–6 hours, and the following phase's half-life is 5–9 hours. The drug is extensively metabolized with 3 or 4 major metabolites having been identified in the human body, some of which such as mCPP may contribute to the side effect profile of trazodone. mCCP has been shown to activate numerous serotonin receptors, including 5ht2c. Due to the short half-life of trazodone, if a dose is taken at night, mCCP would be present in the body during the following day, causing symptoms such as anorexia (behavioral symptoms), anxiety, hypolocomotion, headache, and depression. Approximately 70–75% of C-labelled trazodone was found to be excreted in the urine within 72 hours. Trazodone is highly protein-bound.
Warnings
If the patient has a known hypersensitivity to trazodone.If the patient is under 18 years of age and combines with other antidepressant medications it may increase the possibility of suicidal thoughts or actions.
Precautions
Trazodone is metabolised by CYP3A4, a liver enzyme. Inhibition of this enzyme by various other substances may delay its degradation, leading to high blood levels of trazodone. CYP3A4 may be inhibited by many other medications, herbs, and foods, and as such, trazodone may interact with these substances. One drug-food interaction is grapefruit juice. Drinking grapefruit juice is discouraged in patients taking trazodone. One glass of grapefruit juice occasionally is not likely to have this effect on most people, but drinking large amounts, or drinking it regularly is proven to affect trazodone's clearance.
The possibility of suicide in depressed patients remains during treatment and until significant remission occurs. Therefore, the number of tablets prescribed at any one time should take into account this possibility, and patients with suicidal ideation should never have access to large quantities of trazodone.
Trazodone has been reported to cause seizures in a small number of patients who took it concurrently with other anti seizure medications.
While trazodone is not a true member of the SSRI class of antidepressants, it does still share many properties of the SSRIs, especially the possibility of discontinuation syndrome if the medication is stopped too quickly. Care must therefore be taken when coming off the medication, usually by a gradual process of tapering down the dose over a period of time.
A person who abruptly stops taking trazodone, even in doses as low as 25 mg (common for use as a sleep aid for people with anxiety disorders), may experience adverse mental reactions such as emotional instability, depressed mood, and suicidal thoughts. Although such warnings may be included in printed materials supplied with the drug, physicians prescribing trazodone, particularly those who are not psychiatrists, might not give oral warnings.
Pregnancy and lactation
Pregnancy: Sufficient data in humans is lacking. Use should be justified by the severity of the condition to be treated.Lactation: Sufficient data in humans is also lacking. Additionally, trazodone may be found in the maternal milk in significant concentrations. Women should not breastfeed while taking trazodone.
Side effects
The most common adverse reactions encountered are drowsiness, nausea/vomiting, headache and dry mouth. Adverse reactions reported include the following:
Behavioral
Drowsiness, fatigue, lethargy, psychomotor retardation, lightheadedness, dizziness, difficulty in concentration, confusion, memory loss, uncontrollable laughter, sex drive decrease.
Neurological
Tremor, headache, ataxia, migraine, akathisia, muscle stiffness, slurred speech, slowed speech, vertigo, tinnitus, tingling of extremities, paresthesia, weakness, complex partial seizures, and rarely, impaired speech, muscle twitching, numbness, dystonia, euphoria, and involuntary movements.
Autonomic
Dry or numb mouth, blurred vision, priapism, diplopia, miosis, nasal congestion, constipation, sweating, urinary retention, increased urinary frequency and incontinence.
Cardiovascular
Hypotension, tachycardia, palpitations, shortness of breath, apnea, syncope, arrhythmias, prolonged P-R interval, atrial fibrillation, bradycardia, ventricular ectopic activity (including ventricular tachycardia), myocardial infarction, and cardiac arrest.
Rare side effects
Recent clinical studies in patients with pre-existing cardiac disease indicate that trazodone may be arrhythmogenic in some patients in that population. Arrhythmias identified include isolated PVC's, ventricular couplets, and in 2 patients short episodes (3 to 4 beats) of ventricular tachycardia. There have also been several post-marketing reports of arrhythmias in trazodone-treated patients who have pre-existing cardiac disease and in some patients who did not have pre-existing cardiac disease. Until the results of prospective studies are available, patients with pre-existing cardiac disease should be closely monitored, particularly for cardiac arrhythmias. Trazodone is not recommended for use during the initial recovery phase of myocardial infarction.
Priapism
Trazodone has rarely been associated with the occurrence of priapism. In approximately 33% of the cases reported, surgical intervention was required and, in a portion of these cases, permanent impairment of erectile function or impotence resulted.
Priapism is a potentially harmful medical condition in which the erect penis does not return to its flaccid state (despite the absence of both physical and psychological stimulation) within about four hours. It is often painful. Male patients with prolonged or inappropriate erections should immediately discontinue the drug and consult their physician. If the condition persists for more than 24 hours, it would be advisable for the treating physician to consult a urologist or appropriate specialist in order to decide on a management approach.
In women, a similar condition of persistent arousal can be caused and is called persistent genital arousal disorder.
Gastrointestinal
Nausea, vomiting, diarrhea, gastrointestinal discomfort, anorexia, increased appetite.
Liver
Rare cases of idiosyncratic hepatotoxicity have been observed, possibly due to the formation of reactive metabolites.
Endocrine
Decrease and, more rarely, increase in libido, weight gain and loss, and rarely, menstrual irregularities, retrograde ejaculation and inhibition of ejaculation.
Elevated prolactin concentrations have been observed in patients taking trazodone.
Allergic or toxic
Skin rash, itching, edema, and, rarely, hemolytic anemia, methemoglobinemia, liver enzyme alterations, obstructive jaundice, leukocytoclastic vasculitis, purpuric maculopapular eruptions, photosensitivity and fever.
Miscellaneous
Aching joints and muscles, hypersalivation, chest pain, hematuria, red, tired and itchy eyes. muscle twitches
Occupational hazards
Since trazodone may impair the mental and/or physical abilities required for performance of potentially hazardous tasks, such as operating an automobile or machinery, the patient should be cautioned not to engage in such activities while impaired.
Laboratory tests
It is recommended that white blood cell and differential counts should be performed in patients who develop sore throat, fever, or other signs of infection or blood dyscrasia and trazodone should be discontinued if the white blood cell or absolute neutrophil count falls below normal.
Drug interactions
Trazodone may enhance the effects of alcohol, barbiturates and other CNS depressants; patients should be cautioned accordingly as trazodone with the combination of another CNS depressant, can result in extreme tiredness and dizziness.
Increased serum digoxin and phenytoin levels have been reported to occur in patients receiving trazodone concurrently with either of those 2 drugs. Little is known about the interaction between trazodone and general anesthetics; therefore, prior to elective surgery, trazodone should be discontinued for as long as clinically feasible.
Because it is not known whether an interaction will occur between trazodone and monoamine oxidase inhibitors (MAOIs), administration of trazodone should be initiated very cautiously with gradual increase in dosage as required, if an MAOIs is given concomitantly or has been discontinued shortly before medication with trazodone is instituted.
Because of the absence of experience, concurrent administration of electroconvulsive therapy should be avoided.
Dosage
Treatment should be started with low initial doses of 25 to 50 mg daily in divided doses or in an evening single dose. The dose may be increased slowly to a maximum of 300 mg daily in ambulatory patients and to 600 mg daily in hospitalized patients. Geriatric and emaciated patients should begin with 25 mg daily; this dose may be slowly increased to 300 mg. The duration of treatment should be at least one month. A 50 mg dose is recommended when using Trazodone as a sleep aid.
Overdose
Symptoms
Overdose of trazodone may cause an increase in incidence or severity of any of the reported adverse reactions, e.g. excessive sedation. Death by deliberate or accidental overdosage has been reported. However, trazodone is often used instead of tricyclic antidepressants because it is very rarely lethal in overdose. Depressed patients are therefore unlikely to successfully commit suicide with trazodone.
Treatment
There is no specific antidote for trazodone. Management of overdosage should, therefore, be symptomatic and supportive. Any person suspected of having taken an overdosage should be evaluated at a hospital as soon as possible. Activated charcoal, gastric lavage, and forced diuresis may be useful in facilitating elimination of the drug.
See also
etoperidoneLubazodone
nefazodone
Vilazodone
| Name | Information | Price* | Quantity |
| Desyrel 50mg | 100 tablets (trazodone) | $111 | 100 tablets |
| Desyrel 50mg/5ml | 120 ml (Trazodone Hydrochloride) | $30 | 120 ml |
| Desyrel 100mg | 100 tablets (trazodone) | $140 | 100 tablets |
| Desyrel 150mg | (discontinued) | N/A | |
| Generic Trazodone 50mg | 84 tablets | $18 | 84 tablets |
| Generic Trazodone 75mg | 100 tablets | $25 | 100 tablets |
| Generic Trazodone 100mg | 100 tablets | N/A | |
| Generic Trazodone 150mg | 100 tablets | N/A |
*) Prices related to some of online drugstores. There are only approximate prices. For some of drugs is needed a prescription.
Tags
Keywords related to trazodone
benzethonium chloride bronitin mist hydromorphinol furoxone chloroptic agrylin tenoxicam oral contraceptive formulations hexamine rezulin clobetasone letrozole lanoxin tensilon eletriptan spiradoline azelastine permapen anileridine oxypertine mefloquine clindagel methadose thiopropazate demoxepam mebeverine arimidex puromycin oprelvekin isoxsuprine estinyl aclarubicin linagliptin acetorphine tazorac amoxicillin eptifibatide cinolazepam embutramide probenecid dithranol ciglitazone lurtotecan candicidin thiomersal oxetacaine alteplase milameline novo nordisk